Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on developing novel therapies for oncology indications, having entered the public markets through its de-SPAC merger with Panacea Acquisition Corp. II, a blank-check company sponsored by Panacea Acquisition Holdings II, LLC and affiliated with Tang Capital Management. The SPAC completed its IPO in 2020, and the business combination closed in February 2022. Nuvation Bio operates in the healthcare and life sciences sector, advancing a pipeline of cancer treatments. The company filed an 8-K with the SEC on May 23, 2025, disclosing a material corporate event. For complete filing details, transaction history, and real-time SPAC data on Nuvation Bio and hundreds of other vehicles, sign up for full access at SpacDesk.